Analyst Price Targets — TIL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 6, 2026 5:18 pm | — | Robert W. Baird | $7.00 | $6.52 | TheFly | Instil Bio downgraded to Neutral from Outperform at Baird |
| September 16, 2024 10:01 am | Jack Allen | Robert W. Baird | $180.00 | $65.58 | StreetInsider | Baird Reiterates Outperform Rating on Instil Bio Inc (TIL) |
| September 16, 2024 6:54 am | Mitchell Kapoor | H.C. Wainwright | $120.00 | $84.52 | StreetInsider | Instil Bio Inc (TIL) PT Raised to $120 at H.C. Wainwright |
| September 12, 2024 7:26 am | Mitchell Kapoor | H.C. Wainwright | $40.00 | $39.19 | StreetInsider | Instil Bio Inc (TIL) PT Raised to $40 at H.C. Wainwright |
| April 12, 2024 2:30 am | Kelly Shi | Jefferies | $11.00 | $11.06 | StreetInsider | Jefferies Downgrades Instil Bio Inc (TIL) to Hold, 'Company Exploring New Avenues Beyond TILs' |
| December 12, 2022 10:44 am | — | Morgan Stanley | $2.00 | $0.84 | Benzinga | Morgan Stanley Maintains Equal-Weight on Instil Bio, Lowers Price Target to $2 |
| June 5, 2022 1:46 pm | Vikram Purohit | Morgan Stanley | $9.00 | $6.01 | TheFly | Instil Bio price target lowered to $9 from $14 at Morgan Stanley |
Latest News for TIL
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and provided a corporate update. Recent Highlights: Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic…
Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop
Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade. Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip was attributed to one-off events, not demand weakness. Gross margin was impacted by temporary costs but is expected to improve to 50%+ as internal manufacturing scales and opex reductions take effect.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TIL.
U.S. House Trading
No House trades found for TIL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.